2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
139 hedge funds and large institutions have $234M invested in 2seventy bio in 2025 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 20 increasing their positions, 42 reducing their positions, and 21 closing their positions.
422% more call options, than puts
Call options by funds: $710K | Put options by funds: $136K
114% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 21
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more capital invested
Capital invested by funds: $135M → $234M (+$99.4M)
20% more funds holding
Funds holding: 116 → 139 (+23)
52% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$13.5M |
| 2 |
Man Group
London,
United Kingdom
|
+$6.49M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$4.22M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$3.63M |
| 5 |
GLF
Groupe la Francaise
Paris,
France
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$17.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.99M |
| 3 |
EP
Eversept Partners
New York
|
-$2.95M |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$2.32M |
| 5 |
VM
Venator Management
Pittsburgh,
Pennsylvania
|
-$1.69M |
TSVT Hedge Fund Activity: Q1 2025 in Review
139 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q1 2025, worth a combined $234M — up 74% from $135M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new TSVT positions and 21 closed out — a net gain of 24 holders — while 20 added to existing stakes and 42 trimmed.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $13.5M. The largest seller was Kynam Capital Management, exiting entirely with an estimated $17.5M sold.
- 139 institutional investors held 2seventy bio (TSVT) as of Q1 2025, up from 116 in Q4 2024.
- Funds reported $234M of 2seventy bio stock for Q1 2025, up 74% quarter-over-quarter.
- 45 funds opened new 2seventy bio positions in Q1 2025 and 21 closed out, a net change of +24 holders.
- The largest 2seventy bio buyer in Q1 2025 was Beryl Capital Management, an estimated $13.5M added.
- The largest 2seventy bio seller in Q1 2025 was Kynam Capital Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q1 2025.